Yasmeen Rahimi
Stock Analyst at Piper Sandler
Total Price Targets
26
Stocks Covered
19
Sectors
Healthcare, Technology
Most Recent
Mar 12, 2026
Notable Calls (Last 12 Months)
Most Bullish
Stocks Covered by Yasmeen Rahimi
| Symbol | Company | Latest Target | Current Price | Upside | # Targets | Last Updated |
|---|---|---|---|---|---|---|
| PLRX | Pliant Therapeutics, Inc. | $3.00 | $1.23 | +144.9% | 2 | Mar 12, 2026 |
| ARCT | Arcturus Therapeutics Holdings Inc. | $25.00 | $8.64 | +189.2% | 2 | Mar 4, 2026 |
| NKTR | Nektar Therapeutics | $105.00 | $86.71 | +21.1% | 1 | Jan 26, 2026 |
| MDGL | Madrigal Pharmaceuticals, Inc. | $900.00 | $516.66 | +74.2% | 2 | Dec 19, 2025 |
| PRAX | Praxis Precision Medicines, Inc. | $450.00 | $330.59 | +36.1% | 1 | Dec 5, 2025 |
| PRTA | Prothena Corporation plc | $36.00 | $10.86 | +231.5% | 1 | Oct 28, 2025 |
| UPB | Upstream Bio, Inc. | $75.00 | $9.31 | +705.6% | 1 | Nov 5, 2024 |
| ANAB | AnaptysBio, Inc. | $80.00 | $66.67 | +20.0% | 1 | Oct 15, 2024 |
| EWTX | Edgewise Therapeutics, Inc. | $51.00 | $30.63 | +66.5% | 2 | Oct 11, 2024 |
| BNTC | Benitec Biopharma Inc. | $30.00 | $11.98 | +150.4% | 1 | Sep 24, 2024 |
| NAMS | NewAmsterdam Pharma Company N.V. | $37.00 | $28.65 | +29.1% | 1 | Sep 23, 2024 |
| VRNS | Varonis Systems, Inc. | $48.00 | $26.48 | +81.3% | 2 | Jul 30, 2024 |
| CYTK | Cytokinetics, Incorporated | $107.00 | $64.40 | +66.1% | 2 | Jun 10, 2024 |
| IMVT | Immunovant, Inc. | $57.00 | $27.11 | +110.2% | 1 | May 30, 2024 |
| SLNO | Soleno Therapeutics, Inc. | $93.00 | $52.86 | +75.9% | 1 | May 23, 2024 |
| DSGN | Design Therapeutics, Inc. | $12.00 | $13.29 | -9.7% | 2 | May 7, 2024 |
| CRNX | Crinetics Pharmaceuticals, Inc. | $97.00 | $38.93 | +149.2% | 1 | May 7, 2024 |
| ALT | Altimmune, Inc. | $25.00 | $2.78 | +799.3% | 1 | Aug 30, 2022 |
| ENTA | Enanta Pharmaceuticals, Inc. | $87.00 | $14.22 | +511.6% | 1 | Jul 29, 2022 |
Recent Activity
- Mar 12, 2026— Set$3.00price target onPLRX(Pliant Therapeutics, Inc.)
- Mar 4, 2026— Set$25.00price target onARCT(Arcturus Therapeutics Holdings Inc.)
- Jan 26, 2026— Set$105.00price target onNKTR(Nektar Therapeutics)
- Dec 19, 2025— Set$900.00price target onMDGL(Madrigal Pharmaceuticals, Inc.)
- Dec 5, 2025— Set$450.00price target onPRAX(Praxis Precision Medicines, Inc.)
- Oct 28, 2025— Set$36.00price target onPRTA(Prothena Corporation plc)
- Nov 5, 2024— Set$75.00price target onUPB(Upstream Bio, Inc.)
- Oct 15, 2024— Set$80.00price target onANAB(AnaptysBio, Inc.)
- Oct 11, 2024— Set$51.00price target onEWTX(Edgewise Therapeutics, Inc.)
- Sep 24, 2024— Set$30.00price target onBNTC(Benitec Biopharma Inc.)
- Sep 23, 2024— Set$37.00price target onNAMS(NewAmsterdam Pharma Company N.V.)
- Jul 30, 2024— Set$48.00price target onVRNS(Varonis Systems, Inc.)
- Jul 1, 2024— Set$48.00price target onEWTX(Edgewise Therapeutics, Inc.)
- Jun 10, 2024— Set$107.00price target onCYTK(Cytokinetics, Incorporated)
- May 31, 2024— Set$20.02price target onARCT(Arcturus Therapeutics Holdings Inc.)
- May 30, 2024— Set$57.00price target onIMVT(Immunovant, Inc.)
- May 29, 2024— Set$336.00price target onMDGL(Madrigal Pharmaceuticals, Inc.)
- May 23, 2024— Set$93.00price target onSLNO(Soleno Therapeutics, Inc.)
- May 23, 2024— Set$40.00price target onPLRX(Pliant Therapeutics, Inc.)
- May 7, 2024— Set$97.00price target onCRNX(Crinetics Pharmaceuticals, Inc.)
Frequently Asked Questions
Who is Yasmeen Rahimi?
Yasmeen Rahimi is a stock analyst at Piper Sandler covering 19 stocks primarily in Healthcare, Technology. They have issued 26 price targets since Jun 9, 2022.
What stocks does Yasmeen Rahimi cover?
Yasmeen Rahimi currently covers 19 stocks, including PLRX, ARCT, MDGL, EWTX, VRNS.
What is Yasmeen Rahimi's latest price target?
Yasmeen Rahimi's most recent price target was $3.00 on PLRX (Pliant Therapeutics, Inc.), set on Mar 12, 2026.
What is Yasmeen Rahimi's highest price target?
Yasmeen Rahimi's highest issued price target is $900.00 on MDGL, set on Dec 19, 2025.
More Analysts at Piper Sandler
Coverage based on publicly published price targets. Not investment advice.